Scott Davis - Ekso Bionics Chief Officer
| EKSO Stock | USD 0.62 0.02 2.97% |
Executive
Scott Davis is Chief Officer of Ekso Bionics Holdings
| Age | 55 |
| Address | 101 Glacier Point, San Rafael, CA, United States, 94901 |
| Phone | 510 984 1761 |
| Web | https://www.eksobionics.com |
Scott Davis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Davis against Ekso Bionics stock is an integral part of due diligence when investing in Ekso Bionics. Scott Davis insider activity provides valuable insight into whether Ekso Bionics is net buyers or sellers over its current business cycle. Note, Ekso Bionics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ekso Bionics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Davis over two months ago Acquisition by Scott Davis of 94595 shares of Noodles subject to Rule 16b-3 |
Ekso Bionics Management Efficiency
The company has return on total asset (ROA) of (0.2417) % which means that it has lost $0.2417 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7389) %, meaning that it created substantial loss on money invested by shareholders. Ekso Bionics' management efficiency ratios could be used to measure how well Ekso Bionics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of January 2025, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to drop to -0.69. At this time, Ekso Bionics' Non Currrent Assets Other are very stable compared to the past year. As of the 23rd of January 2025, Intangible Assets is likely to grow to about 5.9 M, while Total Assets are likely to drop about 26 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Naomi Phaneuf | Femasys | N/A | |
| Jeffrey DiRubio | Precision Optics, | N/A | |
| Marcena Clawson | Utah Medical Products | N/A | |
| Addam Chupa | InfuSystems Holdings | 46 | |
| Brian Koopman | Utah Medical Products | 55 | |
| Christine Thomas | Femasys | 52 | |
| Judy CFA | Nephros | 60 | |
| Priyam Shah | Akoya Biosciences | N/A | |
| Clay Schwabe | Precision Optics, | N/A | |
| Jennifer Kamocsay | Akoya Biosciences | 54 | |
| Wolfgang Becker | Straumann Holding AG | 57 | |
| James MD | Femasys | N/A | |
| Richard Spector | Femasys | 54 | |
| Brianne McGuire | Nephros | N/A | |
| James JD | Milestone Scientific | N/A | |
| Maik Helmers | LeMaitre Vascular | 51 | |
| JD CFA | Akoya Biosciences | N/A | |
| Mahesh Lawande | Precision Optics, | 52 | |
| MS MBA | Nephros | 50 | |
| Jeanie Latz | InfuSystems Holdings | N/A | |
| Mark Fox | Utah Medical Products | N/A | |
Management Performance
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.24 |
Ekso Bionics Holdings Leadership Team
Elected by the shareholders, the Ekso Bionics' board of directors comprises two types of representatives: Ekso Bionics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ekso. The board's role is to monitor Ekso Bionics' management team and ensure that shareholders' interests are well served. Ekso Bionics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ekso Bionics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephan Aderhold, Senior EMEA | ||
| Steven Sherman, Chairman of the Board | ||
| Foon Chwee, President APAC | ||
| Rachael Anderson, Global Growth | ||
| Scott Davis, Chief Officer | ||
| Ann Cookson, Human Director | ||
| Katherine Strausser, Principal Engineer | ||
| Jason Jones, Chief Officer | ||
| Jerome Wong, Corporate Controller | ||
| Anthony Pratt, Vice Sales |
Ekso Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ekso Bionics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 11.98 M | ||||
| Shares Outstanding | 22 M | ||||
| Shares Owned By Insiders | 7.91 % | ||||
| Shares Owned By Institutions | 25.25 % | ||||
| Number Of Shares Shorted | 240.34 K | ||||
| Price To Earning | (0.67) X |
Pair Trading with Ekso Bionics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ekso Bionics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ekso Bionics will appreciate offsetting losses from the drop in the long position's value.Moving against Ekso Stock
| 0.85 | LNSR | LENSAR Inc | PairCorr |
| 0.81 | HSTM | HealthStream | PairCorr |
| 0.68 | HQY | HealthEquity | PairCorr |
| 0.67 | CAH | Cardinal Health Earnings Call This Week | PairCorr |
| 0.64 | HIMS | Hims Hers Health Aggressive Push | PairCorr |
The ability to find closely correlated positions to Ekso Bionics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ekso Bionics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ekso Bionics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ekso Bionics Holdings to buy it.
The correlation of Ekso Bionics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ekso Bionics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ekso Bionics Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ekso Bionics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.